At the recent Association of Women in Rheumatology annual conference, AWIR and ACR leaders discussed advocacy’s important role in supporting equitable rheumatologic care.
Lowest Price, Highest Risk? New Drug Policy’s Potential Effect on Rheumatology
On July 31, President Trump sent formal letters to the CEOs of 17 major pharmaceutical companies, laying out several requirements the companies must meet within 60 days or face unspecified consequences. These include Most-Favored-Nation pricing for Medicare, Medicaid and private markets.
Rheumatology Could Face New Challenges Under Drug Tariff Reforms
A 15% tariff on all European Union exports, including pharmaceuticals, went into effect on Aug. 7. The tariff could impact the cost of providing care, patient access to therapies and drug research and development.
DOJ Tightens Oversight of DEI Programs: Implications for Rheumatology
A July 30 memo from Attorney General Pam Bondi clarifies how federal anti-discrimination laws apply to programs that might involve discriminatory practices, including those that fall under the umbrella of diversity, equity and inclusion.
Countdown to ACR Convergence 2025: Early Registration Ends Aug. 21
Learn about the registration options and add-on opportunities associated with ACR Convergence 2025, to be held Oct. 24–29 in Chicago, Ill.
The What, Why & How of MIPS Exception Applications
Practices that have experienced extreme circumstances—including wildfires or flooding—can apply for exceptions for Quality Payment Program reporting. Applications for 2025 are open through Dec. 31.
The ACR Advocates for Reinstatement of Members of CDC’s Advisory Committee on Immunization Practices
With 20 partner organizations, the ACR submitted a letter to HHS Secretary Robert F. Kennedy, Jr., urging the reinstatement of the terminated experts and reaffirming its commitment to science-based immunization policy.
August Updates from the ACR Insurance Subcommittee
The Insurance Subcommittee of the Committee on Rheumatologic Care is working on behalf of ACR members to address critical coverage and reimbursement challenges.
Results for Novel, Glucocorticoid-Sparing Treatment for Patients with PMR
A phase 2 study from Spiera et al. found that patients with glucocorticoid-dependent PMR taking the antibody-drug conjugate ABBV-154 had a longer time to flare compared with those taking placebo, supporting further investigation.
JAK Inhibitors 101
Experts provided an in-depth review of Janus kinase (JAK) inhibitors, discussing the latest research on their use in the treatment of specific rheumatic conditions, the risks associated with them and more.
- 1
- 2
- 3
- …
- 322
- Next Page »